Please login to the form below

Not currently logged in
Email:
Password:

Dextroamphetamine

This page shows the latest Dextroamphetamine news and features for those working in and with pharma, biotech and healthcare.

Shire weathers generic Adderall XR challenge

Shire weathers generic Adderall XR challenge

attention deficit-hyperactivity disorder (ADHD) drug Adderall XR (amphetamine and dextroamphetamine).

Latest news

  • Shire's Q3 net profit doubles

    Products that performed particularly well in the quarter included ADHD treatments Vyvanse (lisdexamfetamine) and Adderall XR (amphetamine, dextroamphetamine mixed salts).

  • Shire ADHD scholarship programme

    use as adjunctive therapy to stimulants; the extended-release drug Vyvanse (lisdexamfetamine dimesylate), which was approved in the US in 2007; and Adderall XR (dextroamphetamine and amphetamine), which was approved in

  • New use cleared for Shire ADHD drug

    The company's ADHD portfolio also includes the extended-release drug VyVanse (lisdexamfetamine dimesylate), which was approved in the US in 2007, and Adderall XR (dextroamphetamine and amphetamine), which was approved

  • Malcolm's Market Eye: 28 July to 3 August 2007

    Shire wants the drug to take over from Adderall XR (amphetamine/dextroamphetamine), its blockbuster drug now threatened by generic competition, because in 2009 it loses patent protection.

  • Malcolm's Market Eye, 27 February 2007

    Shire has gained full control over Vyvanse, as it needs a successor to Adderall XR (amphetamine/ dextroamphetamine extended-release), its biggest-selling ADHD drug, which soon loses patent protection.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics